79 related articles for article (PubMed ID: 23350445)
1. [Importance and practice of UGT1A1 polymorphisms].
Watanabe A; Shimada T
Nihon Rinsho; 2012 Sep; 70 Suppl 7():475-9. PubMed ID: 23350445
[No Abstract] [Full Text] [Related]
2. [Importance and practice of UGT1A1 polymorphisms].
Hazama S; Oka M
Nihon Rinsho; 2011 Apr; 69 Suppl 3():351-4. PubMed ID: 22213983
[No Abstract] [Full Text] [Related]
3. [Treatment with CPT-11 based on the UGT1A1 genetic polymorphism].
Nishi T; Komaki T; Hamamoto Y
Nihon Rinsho; 2011 Apr; 69 Suppl 3():545-9. PubMed ID: 22214020
[No Abstract] [Full Text] [Related]
4. UGT1A1 polymorphism predicts irinotecan toxicity: evolving proof.
Mani S
AAPS PharmSci; 2001; 3(3):3. PubMed ID: 11783425
[No Abstract] [Full Text] [Related]
5. UGT1A1 genotyping in patients undergoing treatment with irinotecan.
Innocenti F
Clin Adv Hematol Oncol; 2005 Nov; 3(11):843-4. PubMed ID: 16491625
[No Abstract] [Full Text] [Related]
6. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
Biason P; Masier S; Toffoli G
J Chemother; 2008 Apr; 20(2):158-65. PubMed ID: 18467239
[TBL] [Abstract][Full Text] [Related]
7. Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy.
Akiyama Y; Fujita K; Nagashima F; Yamamoto W; Endo H; Sunakawa Y; Yamashita K; Ishida H; Mizuno K; Araki K; Ichikawa W; Miya T; Narabayashi M; Kawara K; Sugiyama M; Hirose T; Ando Y; Sasaki Y
Ann Oncol; 2008 Dec; 19(12):2089-90. PubMed ID: 18953066
[No Abstract] [Full Text] [Related]
8. Pharmacogenetic approach for cancer treatment-tailored medicine in practice.
Hasegawa Y; Ando Y; Ando M; Hashimoto N; Imaizumi K; Shimokata K
Ann N Y Acad Sci; 2006 Nov; 1086():223-32. PubMed ID: 17185519
[TBL] [Abstract][Full Text] [Related]
9. Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay.
Hasegawa Y; Sarashina T; Ando M; Kitagawa C; Mori A; Yoneyama M; Ando Y; Shimokata K
Clin Chem; 2004 Aug; 50(8):1479-80. PubMed ID: 15277366
[No Abstract] [Full Text] [Related]
10. UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.
Ando Y; Fujita K; Sasaki Y; Hasegawa Y
Curr Opin Mol Ther; 2007 Jun; 9(3):258-62. PubMed ID: 17608024
[TBL] [Abstract][Full Text] [Related]
11. Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay.
Hasegawa Y; Ando Y; Shimokata K
Expert Rev Mol Diagn; 2006 Jul; 6(4):527-33. PubMed ID: 16824027
[TBL] [Abstract][Full Text] [Related]
12. [Irinotecan and liver dysfunctions].
Sablin MP; Le Tourneau C; Faivre S; Raymond E
Therapie; 2007; 62(2):111-5. PubMed ID: 17582311
[TBL] [Abstract][Full Text] [Related]
13. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.
Sakaguchi S; Garcia-Bournissen F; Kim R; Schwarz UI; Nathan PC; Ito S
Arch Dis Child; 2009 Dec; 94(12):981-2. PubMed ID: 19608554
[TBL] [Abstract][Full Text] [Related]
14. Re: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.
Ichikawa W; Araki K; Fujita K; Yamamoto W; Endo H; Nagashima F; Tanaka R; Miya T; Kodama K; Sunakawa Y; Narabayashi M; Ando Y; Akiyama Y; Kawara K; Sasaki Y
J Natl Cancer Inst; 2008 Feb; 100(3):224-5; author reply 225. PubMed ID: 18230796
[No Abstract] [Full Text] [Related]
15. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
Fakih MG; Ross ME; Starostik P
Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan in small-cell lung cancer.
Ando Y; Figg WD
N Engl J Med; 2002 May; 346(18):1414-5; author reply 1414-5. PubMed ID: 11986422
[No Abstract] [Full Text] [Related]
17. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
[TBL] [Abstract][Full Text] [Related]
18. Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis.
Hu ZY; Yu Q; Zhao YS
Eur J Cancer; 2010 Jul; 46(10):1856-65. PubMed ID: 20335017
[TBL] [Abstract][Full Text] [Related]
19. UGT1A and irinotecan toxicity: keeping it in the family.
Hoskins JM; McLeod HL
J Clin Oncol; 2009 May; 27(15):2419-21. PubMed ID: 19364959
[No Abstract] [Full Text] [Related]
20. Irinotecan pharmacogenetics: is it time to intervene?
McLeod HL; Watters JW
J Clin Oncol; 2004 Apr; 22(8):1356-9. PubMed ID: 15007084
[No Abstract] [Full Text] [Related]
[Next] [New Search]